Free Access
Med Sci (Paris)
Volume 24, Number 1, Janvier 2008
Page(s) 7 - 9
Section Nouvelles
Published online 15 January 2008
  1. Barre-Sinoussi F, Chermann JC, Rey M, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220 : 868–71. [Google Scholar]
  2. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384 : 529–34. [Google Scholar]
  3. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272 : 1167–70. [Google Scholar]
  4. Costagliola D, Downs AM. Incubation time for AIDS. Nature 1987; 328 : 582. [Google Scholar]
  5. Buchbinder SP, Katz MN, Hessol NA, et al. Long-term HIV-1 infection without immunologic progression. AIDS 1994; 8 : 1123–8. [Google Scholar]
  6. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers : a homogeneous group of HIV-1-infected patients with spontaneous cont rol of viral replication. Clin Infect Dis 2005; 41 : 1053–6. [Google Scholar]
  7. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332 : 201–8. [Google Scholar]
  8. Candotti D, Costagliola D, Joberty C, et al. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J Med Virol 1999; 58 : 256–263. [Google Scholar]
  9. Magierowska M, Theodorou I, Debre P, et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1- infected individuals. Blood 1999; 93 : 936–41. [Google Scholar]
  10. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection : a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181 : 1365–72. [Google Scholar]
  11. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278 : 47–1450. [Google Scholar]
  12. Martinez V, Costagliola D, Bonduelle O, et al. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 2005; 191 : 2053–63. [Google Scholar]
  13. Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007; 81 : 2508–18. [Google Scholar]
  14. Lamine A, Caumont-Sarcos A, Chaix ML, et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 2007; 21 : 1043–5. [Google Scholar]
  15. Sajadi MM, Heredia A, Le N, et al. HIV-1 natural viral suppressors : control of viral replication in the absence of therapy. AIDS 2007; 21 : 517–9. [Google Scholar]
  16. Saez-Cirion A, Lacabaratz C, Lambotte M, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104 : 6776–81. [Google Scholar]
  17. Emu B, Sinclair E, Favre D, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79 : 14169–78. [Google Scholar]
  18. Addo MM, Draenert R, Rathod A, et al. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One 2007; 2 : e321. [Google Scholar]
  19. Bailey JR, Williams TM, Siliciano RF, et al. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 2006; 203 : 1357–69. [Google Scholar]
  20. Bailey JR, Lassen KG, Yang HC, et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006; 80 : 4758–70. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.